LYNBROOK, N.Y., Nov. 2, 2016 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical companythat originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX® in the U.S. and Xiapex® in Europe announced
In order to participate in the conference call, please dial 1-866-364-3867 (domestic) or 1-412-902-4213 (international). The live webcast can be accessed under "Events and Presentation" in the "Investors" section of the Company's website at www.biospecifics.com or you may use the link: https://www.webcaster4.com/Webcast/Page/967/17954
A replay of the call will be available one hour after the end of the conference call on November 9, 2016 until 5:00 p.m. ET on November 16, 2016. To access the replay, please dial 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and reference the access code 10095321. The archived webcast will be available for ninety days in the Investors section of BioSpecifics' website at www.biospecifics.com.
About BioSpecifics Technologies Corp.
BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications to date. Injectable collagenase is marketed as XIAFLEX® in the U.S. for the treatment of Dupuytren's contracture and Peyronie's disease by BioSpecifics' partner, Endo International plc (Endo). XIAFLEX® is also commercialized in Japan, Europe, Canada and Australia for Dupuytren's contracture and also for Peyronie's disease in Europe and Australia. Endo has the following partnerships outside the U.S. for these two indications; Swedish Orphan Biovitrum AB has marketing rights for Xiapex® (the European tradename for XIAFLEX) in 71 Eurasian and African countries, Actelion Pharmaceuticals Ltd. has marketing rights in Canada and Australia and Asahi Kasei Pharma Corporation has marketing rights in Japan. Sobi is selling Xiapex in Europe for the treatment of Dupuytren's contracture and Peyronie's disease. Asahi is selling XIAFLEX for the treatment of Dupuytren's contracture in Japan. Actelion is selling XIAFLEX in Canada and Australia for the treatment of Dupuytren's contracture and in Australia for Peyronie's disease. The XIAFLEX development pipeline includes several additional promising indications. Endo is currently managing development of CCH for cellulite, adhesive capsulitis, human and canine lipoma, lateral hip fat and plantar fibromatosis. BioSpecifics is managing the development of CCH for uterine fibroids and plans to initiate clinical development in the fourth quarter of 2016. For more information, please visit www.biospecifics.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biospecifics-technologies-corp-to-report-third-quarter-2016-financial-results-on-wednesday-november-9-2016-300355431.html
SOURCE BioSpecifics Technologies Corp.
Subscribe to our Free Newsletters!
Pets can give you diseases. Surprised? You may love your pet but beware! Your pets might be ...
Water is essential to balance body fluids, boost brain function, improve digestion, prevent ...
Drug hypersensitivity is an adverse reaction that occurs due to an interaction between a drug and ...View All